Clinical Trials Logo
  1. Home
  2. Cystinuria
  3. NCT03663855

Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria

Cystinuria Clinical Trial

Official title:
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria

Clinical Trial Summary

The purpose of this study is to determine the minimum effective dose of the cysteine binding thiol drug (CBTD) Tiopronin on urine cystine capacity, which is a measure of cystine solubility in the urine, in patients with cystinuria to evaluate the effect of escalating doses of cystine binding thiol drugs on the cystine capacity of the urine. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger dosages. Cystinuria is a rare genetic disease that can lead to significant morbidity in affected patients due to the recurrent nature of the disease. This study will follow the levels of urine cystine capacity in order to help guide treatment and to use lower than usually prescribed Tiopronin doses to decrease the potential side effects while maintaining therapeutic benefit. This will increase adherence with the medications by decreasing the burden of the large number of pills that need to be taken daily.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03663855
Study type Interventional
Source NYU Langone Health
Contact
Status Completed
Phase Phase 2
Start date November 1, 2018
Completion date September 10, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02120105 - Cystine Capacity Clinical Study (CysCap)
Completed NCT02538016 - TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT00169806 - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis N/A
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Recruiting NCT02026388 - Rare Kidney Stone Consortium Biobank
Recruiting NCT04818034 - The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study Phase 2
Withdrawn NCT04137978 - Study Evaluating Patients With Cystinuria Phase 2/Phase 3
Recruiting NCT02942420 - Bucillamine Phase 2 Trial in Patients With Cystinuria Phase 2
Completed NCT05048563 - Registry of Thiola EC Therapy
Not yet recruiting NCT04147871 - Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children Phase 2/Phase 3
Completed NCT02125721 - Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Phase 4
Active, not recruiting NCT02910531 - Lipoic Acid Supplement for Cystine Stone Phase 2
Recruiting NCT00588562 - Rare Kidney Stone Consortium Patient Registry
Completed NCT02124395 - Health-related Quality of Life in Rare Kidney Stone
Not yet recruiting NCT05058859 - Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics Phase 2
Active, not recruiting NCT03539926 - This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care). N/A
Completed NCT00381849 - Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones Phase 1/Phase 2
Completed NCT03836144 - Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria